Zubair Bio Consulting

DMPK, biomarker, and translational strategy for preclinical biotech programs.

Zubair Bio Consulting helps biotech teams evaluate DMPK risk, design biomarker strategies, and translate preclinical data into clearer program decisions.

Focused advisory

Identify the risks, evidence gaps, and next studies that matter most.

Expertise

Technical depth with a translational point of view.

DMPK

DMPK strategy for screening, lead optimization, and characterization of small molecules, peptides, and antisense oligonucleotides.

Areas of Support

  • ADME
  • Bioanalysis
  • PK/PD study design
  • DDI risk assessment

Biomarkers

Fit-for-purpose biomarker strategies tailored to each stage of the program.

Areas of Support

  • Discovery biomarkers
  • Target engagement / PD biomarkers
  • Functional and efficacy biomarkers
  • Patient stratification biomarkers

Analytical Technologies

Mass spectrometry and integrated analytical strategies for bioanalysis, biomarker quantitation, and peptide/protein characterization.

Areas of Support

  • MALDI imaging mass spectrometry
  • Proteomics using nano-LC-MS/MS
  • Immunoaffinity-LC-MS workflows
  • Complex sample preparation and enrichment strategies
Faizan Zubair

About

A practical partner for high-stakes science.

About Zubair Bio Consulting

Zubair Bio Consulting provides focused scientific and translational strategy support for biotech teams working across DMPK, biomarker discovery, advanced mass spectrometry, and preclinical drug development.

About Faizan Zubair

Faizan Zubair earned his PhD in Chemical and Biomolecular Engineering and trained in Richard Caprioli's MALDI imaging mass spectrometry laboratory at Vanderbilt University. He brings industry experience from Takeda Pharmaceuticals and Sanofi Genzyme across DMPK, bioanalysis, biomarker strategy, and translational science.

His therapeutic area experience includes gastrointestinal disease, neuroscience, and oncology. Through Zubair Bio Consulting, he helps teams connect complex preclinical data to clearer program strategy, stronger biomarker plans, and more confident preclinical decisions.

Connect with Faizan on LinkedIn

Engagement types

Engagements can include strategic review, study design input, biomarker planning, assay strategy, and scientific diligence.

Contact

Have a program question to work through?

If you are evaluating a DMPK, biomarker, or translational challenge, let's start with the scientific question and identify the clearest path forward.

faizan@zubairbioconsulting.com